A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R

A Multicenter, Randomized, Double-blinded, Active-controlled, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R in Patients With Primary Hypercholesterolemia

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06717360

Enrollment

158

Registered

2024-12-05

Start date

2024-09-30

Completion date

2026-05-12

Last updated

2026-06-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypercholesterolemia

Brief summary

A Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of AG2304T and AG2304R in Patients with Primary Hypercholesterolemia

Interventions

DRUGAG2304T

AG2304T, QD, PO

DRUGAG2304R

AG2304R, QD, PO

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

19 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Adults aged 19-80 * Patients with primary hypercholesterolemia * Those who voluntarily written consent to participate in this clinical trial

Exclusion criteria

* The subject not meet the specified LDL-C level * Other exclusions applied

Design outcomes

Primary

Measure	Time frame
LDL-C level	8 weeks

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 19, 2026